BC Innovations | Apr 30, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiac hypertrophy; heart failure Calcium calmodulin-dependent kinase IIδ (CAMK2D); ryanodine receptor 2 (RyR2) Studies in mice suggest that targeting...
BC Week In Review | Oct 27, 2008
Company News

NitroMed, JHP Pharmaceuticals LLC deal

JHP will acquire NitroMed's BiDil business for $24.5 million in cash, plus up to $1.8 million for inventory. The fixed-dose combination of hydralazine hydrochloride and disosorbide dinitrate is marketed in the U.S. to treat heart...
BC Week In Review | Jan 21, 2008
Clinical News

BiDil XR: Start pivotal trial

In 2009, NitroMed will begin a pivotal bioequivalence trial comparing once-daily BiDil XR to thrice-daily BiDil. NitroMed Inc. (NASDAQ:NTMD), Lexington, Mass.   Product: BiDil XR   Business: Cardiovascular   Molecular target: Not available   Description:...
BC Week In Review | Nov 13, 2006
Clinical News

BiDil XR: Phase II started

NTMD began a Phase II study of once-daily BiDil XR to treat heart failure in African American patients NitroMed Inc. (NTMD), Lexington, Mass.   Product: BiDil XR   Business: Cardiovascular   Molecular target: NA  ...
BC Week In Review | Oct 16, 2006
Company News

NitroMed sales and marketing update

NTMD eliminated its 120-person BiDil sales force to conserve cash and to accelerate development of an extended-release formulation of the product. BiDil is a fixed-dose combination of hydralazine hydrochloride and disosorbide dinitrate that is approved...
BioCentury | Oct 16, 2006
Finance

Ebb & Flow

Like many top tier biotechs, Genentech (DNA) does not provide any product-specific sales guidance, leaving Street forecasters to take their best guess at upcoming sales and earnings. While DNA may or may not care whether...
BC Extra | Oct 12, 2006
Company News

NitroMed cuts sales force

NTMD eliminated its 120-person BiDil sales force to conserve cash to accelerate development of an extended-release formulation of the product, which is a fixed-dose combination of hydralazine hydrochloride and disosorbide dinitrate that is approved to...
Items per page:
1 - 7 of 7